Xiidra, a prescription eye drop used to treat the signs and symptoms of dry eye disease, has not been discontinued [1]. It remains available for patients [2].
What is Xiidra used for?
Xiidra is prescribed to reduce inflammation that contributes to the signs and symptoms of dry eye disease [1].
How does Xiidra work?
Xiidra is an important therapeutic option for dry eye disease because it targets inflammation [1]. It is a lymphocyte function-associated antigen 1 (LFA-1) antagonist that inhibits LFA-1, a protein on the surface of T-cells, thereby blocking the interaction between LFA-1 and its intercellular adhesion molecule (ICAM-1) counterreceptor. This interaction is believed to play a role in the inflammatory processes of dry eye disease [3].
When did Xiidra become available?
Xiidra was approved by the U.S. Food and Drug Administration (FDA) in July 2016 [4].
Who manufactures Xiidra?
Xiidra is manufactured by Bausch + Lomb [1].
What are the potential side effects of Xiidra?
The most common side effects of Xiidra include instillation site reactions, such as burning or stinging in the eye, and changes to taste, such as an unpleasant metallic taste [1]. Other possible side effects include blurred vision, conjunctival hyperemia (redness), and itching [3]. Patients should report any persistent or bothersome side effects to their doctor [1].
What are alternative treatments for dry eye disease?
Besides Xiidra, other treatments for dry eye disease include artificial tears, prescription eye drops like cyclosporine (Restasis) and lifitegrast (Xiidra itself), punctal plugs, and lifestyle modifications [5].
What is the recommended dosage for Xiidra?
Xiidra is typically administered as one drop in each eye twice daily, approximately 12 hours apart [1].
Are there any contraindications for Xiidra?
Xiidra should not be used by individuals with a known hypersensitivity to its ingredients [3].
What is the patent status of Xiidra?
Information regarding Xiidra's patent status, including any patent expirations or challenges, can be found on DrugPatentWatch.com [6].
---
Sources:
[1] Bausch + Lomb. Xiidra Prescribing Information.
[2] Drugs.com. Xiidra.
[3] U.S. Food and Drug Administration. FDA Approves Xiidra (lifitegrast ophthalmic solution) for the Treatment of Dry Eye Disease.
[4] Takeda Pharmaceutical Company. Takeda Announces U.S. FDA Approval of Xiidra (lifitegrast ophthalmic solution) for the Treatment of Signs and Symptoms of Dry Eye Disease.
[5] National Eye Institute. Dry Eye.
[6] DrugPatentWatch.com.